Orevandrodeg

**Semantic type:** Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance

**Definition:** A ligand directed degrader (LDD) composed of an E3 ubiquitin ligase-binding moiety that is conjugated, via a linker, to an as of yet undisclosed moiety that targets a prostate specific tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, orevandrodeg specifically and simultaneously targets and binds to the TAA on prostate tumor cells and to E3 ubiquitin ligase, thereby creating a ternary complex. This induces E3 ligase ubiquitination and proteasome-mediated degradation of the TAA. This prevents TAA-mediated signaling and leads to an inhibition of the growth of tumor cells that overexpress the unidentified TAA.

**Synonyms:** - BMS 986460 - BMS-986460 - BMS986460 - CC-2043137 - LDD BMS-986460 - Ligand Directed Degrader BMS-986460 - Ligand-directed Degrader BMS-986460 - OREVANDRODEG